Table 1 Baseline characteristics of patients screened using sepsis-3 and REWs with and without propensity matching
Characteristics | Total cohort | Propensity matching | ||||
|---|---|---|---|---|---|---|
Sepsis-3 (N = 303) | REWs (N = 176) | p-value | Sepsis-3 (N = 153) | REWs (N = 153) | p-value | |
Male gender,N(%) | 135 (44.6%) | 72 (40.9%) | 0.325 | 71 (46.4%) | 62 (40.5%) | 0.299 |
Age (years), median (IQR) | 72 (71–75) | 71 (68–75) | 0.962 | 71 (68–75) | 71 (67–76) | 0.693 |
Temperature (°C), median (IQR) | 38.3 (38.2–38.6) | 38.7 (38.5–38.8) | 0.024 | 38.7 (38.6–39.0) | 38.7 (38.6–38.9) | 0.943 |
Heart rate (beats/min), median (IQR) | 106 (103–108) | 116 (113–120) | < 0.001 | 112 (110–117) | 116 (113–120) | 0.357 |
Respiratory rate (breaths/min), median (IQR) | 22 (22–24) | 24 (24–28) | 0.001 | 24 (24–26) | 24 (24–28) | 0.192 |
SBP (mmHg), median (IQR) | 130 (126–135) | 129 (122–133) | 0.177 | 124 (118–135) | 129 (122–133) | 0.881 |
SpO2(%), median (IQR) | 96 (96–97) | 96 (95–97) | 0.064 | 95 (94–96) | 96 (95–97) | 0.254 |
Altered mental status,N(%) | 51 (16.8%) | 47 (26.7%) | 0.010 | 32 (20.9%) | 36 (23.5%) | 0.582 |
Comorbidities,N(%) | ||||||
 Cirrhosis | 17 (5.6%) | 4 (2.3%) | 0.085 | 4 (2.5%) | 4 (2.5%) | 1.000 |
 Diabetes mellitus | 122 (40.3%) | 53 (30.1%) | 0.026 | 54 (35.3%) | 51 (33.3%) | 0.718 |
 Hematological malignancy | 19 (6.3%) | 8 (4.5%) | 0.430 | 8 (5.2%) | 8 (5.2%) | 1.000 |
 Non-hematological malignancy | 55 (18.2%) | 37 (21%) | 0.442 | 27 (17.6%) | 32 (20.9%) | 0.469 |
 Transplantation | 10 (3.3%) | 5 (2.8%) | 0.781 | 5 (3.3%) | 4 (2.6%) | 0.735 |
 Immunocompromised | 52 (18.2%) | 37 (21%) | 0.295 | 27 (17.6%) | 32 (20.9%) | 0.469 |
 ESRD on RRT | 24 (7.9%) | 13 (7.4%) | 0.833 | 8 (5.2%) | 11 (7.2%) | 0.477 |
 HFrEF | 9 (3.0%) | 6 (3.4%) | 0.790 | 5 (3.3%) | 4 (2.6%) | 0.735 |
 COPD | 44 (14.5%) | 18 (10.2%) | 0.177 | 22 (14.4%) | 16 (10.5%) | 0.298 |
 Totally dependent for ADL | 50 (16.5%) | 46 (26.1%) | 0.011 | 34 (22.2%) | 36 (23.5%) | 0.785 |
Site of infection | ||||||
 Respiratory system | 120 (39.6%) | 73 (41.5%) | 0.687 | 58 (37.9%) | 65 (42.5%) | 0.414 |
 Urinary tract | 76 (25.1%) | 36 (20.5%) | 0.249 | 37 (24.2%) | 32 (20.9%) | 0.494 |
 Gastrointestinal tract | 43 (14.2%) | 25 (14.2%) | 0.997 | 22 (14.4%) | 21 (13.7%) | 0.869 |
 CNS | 15 (5.0%) | 6 (3.4%) | 0.427 | 6 (3.9%) | 5 (3.3%) | 0.759 |
 Skin | 12 (4.0%) | 9 (5.1%) | 0.552 | 5 (3.3%) | 7 (4.6%) | 0.556 |
 CRBSI | 3 (1.0%) | 2 (1.1%) | 0.879 | 3 (2.0%) | 1 (0.7%) | 0.314 |
 Other | 34 (11.2%) | 25 (14.2%) | 0.338 | 22 (14.4%) | 22 (14.4%) | 1.000 |
Lactate (mmol/L), IQR | 2.10 (2.00–2.30) | 2.35 (2.20–2.60) | 0.001 | 2.20 (2.10–2.50) | 2.30 (2.20–2.70) | 0.342 |
qSOFA (IQR) | 1 (1–2) | 1 (1–2) | < 0.001 | 1 (1–2) | 1 (1–2) | 0.735 |
REWs (IQR) | 4 (4–5) | 5 (5–6) | < 0.001 | 5 (5–6) | 5 (5–6) | 0.730 |